JP2005506350A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005506350A5 JP2005506350A5 JP2003535792A JP2003535792A JP2005506350A5 JP 2005506350 A5 JP2005506350 A5 JP 2005506350A5 JP 2003535792 A JP2003535792 A JP 2003535792A JP 2003535792 A JP2003535792 A JP 2003535792A JP 2005506350 A5 JP2005506350 A5 JP 2005506350A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- optionally substituted
- branched
- unbranched
- pyridinyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 131
- -1 hydroxy, amino Chemical group 0.000 claims 93
- 125000000623 heterocyclic group Chemical group 0.000 claims 30
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 28
- 125000001072 heteroaryl group Chemical group 0.000 claims 23
- 125000003545 alkoxy group Chemical group 0.000 claims 22
- 125000003118 aryl group Chemical group 0.000 claims 21
- 125000004076 pyridyl group Chemical group 0.000 claims 21
- 125000001624 naphthyl group Chemical group 0.000 claims 19
- 125000002252 acyl group Chemical group 0.000 claims 18
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 17
- 125000002757 morpholinyl group Chemical group 0.000 claims 17
- 229910052739 hydrogen Inorganic materials 0.000 claims 16
- 239000001257 hydrogen Substances 0.000 claims 16
- 125000004043 oxo group Chemical group O=* 0.000 claims 16
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 15
- 150000002431 hydrogen Chemical class 0.000 claims 15
- 150000002825 nitriles Chemical class 0.000 claims 14
- 125000004193 piperazinyl group Chemical group 0.000 claims 12
- 229910052736 halogen Inorganic materials 0.000 claims 11
- 150000002367 halogens Chemical class 0.000 claims 11
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 11
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 9
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 9
- 125000002883 imidazolyl group Chemical group 0.000 claims 9
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 9
- 125000003373 pyrazinyl group Chemical group 0.000 claims 9
- 125000002098 pyridazinyl group Chemical group 0.000 claims 9
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 9
- 125000000168 pyrrolyl group Chemical group 0.000 claims 9
- 125000003435 aroyl group Chemical group 0.000 claims 8
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 8
- 125000001041 indolyl group Chemical group 0.000 claims 8
- 229910052757 nitrogen Inorganic materials 0.000 claims 8
- 125000003226 pyrazolyl group Chemical group 0.000 claims 8
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 8
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 8
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 8
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 8
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 8
- 125000005843 halogen group Chemical group 0.000 claims 7
- 125000006602 (C1-C3) alkylsulfonylamino group Chemical group 0.000 claims 6
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 6
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 6
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 6
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 6
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 claims 6
- 125000002971 oxazolyl group Chemical group 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 125000003386 piperidinyl group Chemical group 0.000 claims 6
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims 6
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- 125000000335 thiazolyl group Chemical group 0.000 claims 6
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims 5
- 125000003342 alkenyl group Chemical group 0.000 claims 5
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 claims 5
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 claims 5
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 5
- 125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 claims 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 5
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims 5
- 125000000842 isoxazolyl group Chemical group 0.000 claims 5
- 125000003831 tetrazolyl group Chemical group 0.000 claims 5
- 125000006594 (C1-C3) alkylsulfony group Chemical group 0.000 claims 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 4
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 claims 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 4
- 125000000304 alkynyl group Chemical group 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 4
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 4
- 125000002541 furyl group Chemical group 0.000 claims 4
- 125000005223 heteroarylcarbonyl group Chemical group 0.000 claims 4
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims 4
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims 4
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 125000001544 thienyl group Chemical group 0.000 claims 4
- 125000001246 bromo group Chemical group Br* 0.000 claims 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims 3
- 125000004122 cyclic group Chemical group 0.000 claims 3
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims 3
- 125000001786 isothiazolyl group Chemical group 0.000 claims 3
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 claims 3
- JOZPEVMCAKXSEY-UHFFFAOYSA-N pyrimido[5,4-d]pyrimidine Chemical compound N1=CN=CC2=NC=NC=C21 JOZPEVMCAKXSEY-UHFFFAOYSA-N 0.000 claims 3
- 125000004305 thiazinyl group Chemical group S1NC(=CC=C1)* 0.000 claims 3
- 125000001425 triazolyl group Chemical group 0.000 claims 3
- 125000006698 (C1-C3) dialkylamino group Chemical group 0.000 claims 2
- QYCGBAJADAGLLK-UHFFFAOYSA-N 1-(cyclohepten-1-yl)cycloheptene Chemical group C1CCCCC=C1C1=CCCCCC1 QYCGBAJADAGLLK-UHFFFAOYSA-N 0.000 claims 2
- VSIYJQNFMOOGCU-UHFFFAOYSA-N 1-(cyclohexen-1-yl)cyclohexene Chemical group C1CCCC(C=2CCCCC=2)=C1 VSIYJQNFMOOGCU-UHFFFAOYSA-N 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000009137 Behcet syndrome Diseases 0.000 claims 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 150000004982 aromatic amines Chemical class 0.000 claims 2
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 claims 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 claims 2
- 125000003113 cycloheptyloxy group Chemical group C1(CCCCCC1)O* 0.000 claims 2
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 claims 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims 2
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 claims 2
- 125000005046 dihydronaphthyl group Chemical group 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 2
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 2
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims 2
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 claims 2
- PZTDOGVERGXERN-UHFFFAOYSA-N 1-[4-(3-benzylimidazo[4,5-b]pyridin-6-yl)naphthalen-1-yl]-3-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(C=3C=C4N=CN(CC=5C=CC=CC=5)C4=NC=3)=CC=2)=CC(C(C)(C)C)=N1 PZTDOGVERGXERN-UHFFFAOYSA-N 0.000 claims 1
- SMJMNVALWCFSQR-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-(1-morpholin-4-yl-2,3-dihydro-1h-inden-5-yl)naphthalen-1-yl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NC=2C3=CC=CC=C3C(C=3C=C4CCC(C4=CC=3)N3CCOCC3)=CC=2)=CC(C(C)(C)C)=N1 SMJMNVALWCFSQR-UHFFFAOYSA-N 0.000 claims 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical group C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 206010048768 Dermatosis Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000016604 Lyme disease Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 206010051606 Necrotising colitis Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010044248 Toxic shock syndrome Diseases 0.000 claims 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims 1
- 206010048873 Traumatic arthritis Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000038016 acute inflammation Diseases 0.000 claims 1
- 230000006022 acute inflammation Effects 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000019664 bone resorption disease Diseases 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- 238000007887 coronary angioplasty Methods 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 238000000502 dialysis Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000005293 ferrimagnetic effect Effects 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 210000003714 granulocyte Anatomy 0.000 claims 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 208000004995 necrotizing enterocolitis Diseases 0.000 claims 1
- 125000006574 non-aromatic ring group Chemical group 0.000 claims 1
- 230000008816 organ damage Effects 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 230000000391 smoking effect Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 0 *c1ccc(*)c2ccccc12 Chemical compound *c1ccc(*)c2ccccc12 0.000 description 3
- NVSQEEFQIYSUKY-UHFFFAOYSA-N C=Sc(cc1N2)cnc1OCC2=O Chemical compound C=Sc(cc1N2)cnc1OCC2=O NVSQEEFQIYSUKY-UHFFFAOYSA-N 0.000 description 1
- FPDDDUJKXQFUMU-UHFFFAOYSA-N CC(C)c1cnc2[nH]cnc2c1 Chemical compound CC(C)c1cnc2[nH]cnc2c1 FPDDDUJKXQFUMU-UHFFFAOYSA-N 0.000 description 1
- WIZGGYPJNCGAKV-UHFFFAOYSA-N C[n](cc1)c2c1cncc2 Chemical compound C[n](cc1)c2c1cncc2 WIZGGYPJNCGAKV-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33025401P | 2001-10-18 | 2001-10-18 | |
| PCT/US2002/032809 WO2003032989A1 (en) | 2001-10-18 | 2002-10-11 | 1,4-disubstituted benzo-fused urea compounds as cytokine inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005506350A JP2005506350A (ja) | 2005-03-03 |
| JP2005506350A5 true JP2005506350A5 (enExample) | 2006-01-05 |
Family
ID=23288964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003535792A Pending JP2005506350A (ja) | 2001-10-18 | 2002-10-11 | サイトカイン阻害薬としての１，４−二置換ベンゾ−縮合尿素化合物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US6825184B2 (enExample) |
| EP (1) | EP1438048A1 (enExample) |
| JP (1) | JP2005506350A (enExample) |
| CA (1) | CA2462441A1 (enExample) |
| WO (1) | WO2003032989A1 (enExample) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1408950B1 (en) * | 2001-07-11 | 2007-04-25 | Boehringer Ingelheim Pharmaceuticals Inc. | Methods of treating cytokine mediated diseases |
| EP1455791A1 (en) * | 2001-12-11 | 2004-09-15 | Boehringer Ingelheim Pharmaceuticals Inc. | Method for administering birb 796 bs |
| MXPA04002269A (es) * | 2002-07-09 | 2004-06-29 | Actelion Pharmaceuticals Ltd | Derivados de 7,8,9,10-tetrahidro-6h-azepino,6,7,8,9-tetrahidro-pirido y 2,3-dihidro-2h-pirrolo[2,1-b]-quinazolinona. |
| CN102558155A (zh) | 2003-01-14 | 2012-07-11 | 阿伦纳药品公司 | 作为代谢调节剂的芳基和杂芳基衍生物及其所涉及的疾病如糖尿病和高血糖症的预防和治疗 |
| US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| MXPA05009459A (es) | 2003-03-03 | 2006-05-17 | Array Biopharma Inc | Inhibidores de p38 y sus metodos de uso. |
| JP2007516180A (ja) | 2003-07-02 | 2007-06-21 | スゲン，インコーポレイティド | ｃ−Ｍｅｔ阻害薬としてのアリールメチルトリアゾロおよびイミダゾピラジン類 |
| AR045047A1 (es) | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
| TWI335328B (en) * | 2003-07-14 | 2011-01-01 | Arena Pharm Inc | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related hereto |
| MXPA06001758A (es) * | 2003-08-15 | 2006-08-11 | Irm Llc | Anilino purinas sustituidas en la posicion 6 utiles como inhibidores de rtk. |
| MXPA06002853A (es) * | 2003-09-11 | 2006-06-14 | Kemia Inc | Inhibidores citoquina. |
| TW200530236A (en) * | 2004-02-23 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Heteroaryl phenylurea |
| TW200538453A (en) * | 2004-04-26 | 2005-12-01 | Bristol Myers Squibb Co | Bicyclic heterocycles as kinase inhibitors |
| US7595157B2 (en) * | 2004-08-19 | 2009-09-29 | Biocept, Inc. | Microarrays utilizing hydrogels |
| DE102005017259A1 (de) * | 2005-04-14 | 2006-10-19 | Merck Patent Gmbh | Purinderivate |
| DE102005037499A1 (de) * | 2005-08-09 | 2007-02-15 | Merck Patent Gmbh | Pyrazolderivate |
| JP2009522363A (ja) * | 2006-01-04 | 2009-06-11 | ローカス ファーマシューティカルズ、インク． | プロテインキナーゼの阻害剤 |
| AU2007210073B2 (en) * | 2006-01-31 | 2011-10-06 | Array Biopharma Inc. | Kinase inhibitors and methods of use thereof |
| US7981893B2 (en) * | 2006-10-19 | 2011-07-19 | Signal Pharmaceuticals, Llc | Heteroaryl compounds, compositions thereof, and methods of treatment therewith |
| EP2200443B2 (en) * | 2007-09-17 | 2021-06-30 | Cornell University | Branched chain fatty acids for prevention or treatment of gastrointestinal disorders |
| PE20091552A1 (es) * | 2008-02-06 | 2009-10-25 | Glaxo Group Ltd | Farmacoforos duales - antagonistas muscarinicos de pde4 |
| AR070563A1 (es) * | 2008-02-06 | 2010-04-21 | Glaxo Group Ltd | Compuesto de un biciclo condensado pirazol-piridin-amina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento de enfermedades respiratorias. |
| PE20091553A1 (es) * | 2008-02-06 | 2009-10-30 | Glaxo Group Ltd | Farmacoforos duales - antagonistas muscarinicos de pde4 |
| US7960377B2 (en) | 2008-03-28 | 2011-06-14 | Cara Therapeutics, Inc. | Substituted pyridoxazines |
| US8110578B2 (en) | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
| WO2011021678A1 (ja) * | 2009-08-21 | 2011-02-24 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| NZ618135A (en) | 2009-10-26 | 2015-05-29 | Signal Pharm Llc | Methods of synthesis and purification of heteroaryl compounds |
| MX2013003184A (es) | 2010-09-22 | 2013-06-07 | Arena Pharm Inc | Moduladores del receptor gpr119 y el tratamiento de transtornos relacionados con el mismo. |
| WO2012167053A1 (en) * | 2011-06-01 | 2012-12-06 | Janus Biotherapeutics, Inc. | Novel immune system modulators |
| KR101978537B1 (ko) | 2011-10-19 | 2019-05-14 | 시그날 파마소티칼 엘엘씨 | Tor 키나제 억제제를 사용한 암의 치료 |
| US9403829B2 (en) | 2011-12-02 | 2016-08-02 | Signal Pharmaceuticals, Llc | Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1H)-one, a solid form thereof and methods of their use |
| JP6114317B2 (ja) | 2012-02-24 | 2017-04-12 | シグナル ファーマシューティカルズ，エルエルシー | Ｔｏｒキナーゼ阻害剤の組合せ療法を用いて、非小細胞肺がんを処置する方法 |
| MX2015003874A (es) * | 2012-09-26 | 2015-12-16 | Univ California | Modulacion de ire1. |
| AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
| MX2015009209A (es) | 2013-01-16 | 2016-03-17 | Signal Pharm Llc | Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y metodos de tratamiento con los mismos. |
| US9505764B2 (en) | 2013-04-17 | 2016-11-29 | Signal Pharmaceuticals, Llc | Treatment of cancer with dihydropyrazino-pyrazines |
| HK1221168A1 (zh) | 2013-04-17 | 2017-05-26 | 西格诺药品有限公司 | 用於治疗癌症的包括tor激酶抑制剂和n-(3-(5-氟-2-(4-(2-甲氧基乙氧基)苯基氨基)嘧啶-4-基氨基)苯基)丙烯醯胺的组合疗法 |
| MX368286B (es) | 2013-04-17 | 2019-09-27 | Signal Pharm Llc | Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer. |
| EA030726B1 (ru) | 2013-04-17 | 2018-09-28 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | ФАРМАЦЕВТИЧЕСКИЕ СОСТАВЫ, СПОСОБЫ, ТВЕРДЫЕ ФОРМЫ И СПОСОБЫ ПРИМЕНЕНИЯ, ОТНОСЯЩИЕСЯ К 1-ЭТИЛ-7-(2-МЕТИЛ-6-(1H-1,2,4-ТРИАЗОЛ-3-ИЛ)ПИРИДИН-3-ИЛ)-3,4-ДИГИДРОПИРАЗИНО[2,3-b]ПИРАЗИН-2(1H)-ОНУ |
| AU2014254059B2 (en) | 2013-04-17 | 2019-06-06 | Signal Pharmaceuticals, Llc | Combination therapy comprising a TOR kinase inhibitor and a cytidine analog for treating cancer |
| CA2908957C (en) | 2013-04-17 | 2021-05-18 | Signal Pharmaceuticals, Llc | Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer |
| CA2908353C (en) | 2013-04-17 | 2021-11-02 | Signal Pharmaceuticals, Llc | Treatment of cancer with dihydropyrazino-pyrazines |
| HK1223286A1 (zh) | 2013-05-29 | 2017-07-28 | 西格诺药品有限公司 | 7-(6-(2-羟基丙-2-基)吡啶-3-基)-1-((反式)-4-甲氧基环己基)-3，4-二氢吡嗪并[2，3-b]吡嗪-2(1h)-酮的药物组合物、其固体形式及它们的使用方法 |
| GB201321735D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| WO2015086519A1 (en) * | 2013-12-09 | 2015-06-18 | Ucb Biopharma Sprl | Imidazopyridine derivatives as modulators of tnf activity |
| GB201321739D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| JP2017511367A (ja) | 2014-04-16 | 2017-04-20 | シグナル ファーマシューティカルズ，エルエルシー | １−エチル−７−（２−メチル−６−（１Ｈ−１，２，４−トリアゾール−３−イル）ピリジン−３−イル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オン及び共形成物を含む固体形態、その組成物及び使用方法 |
| EP3131552B1 (en) | 2014-04-16 | 2020-07-15 | Signal Pharmaceuticals, LLC | Methods for treating cancer using tor kinase inhibitor combination therapy |
| US9718824B2 (en) | 2014-04-16 | 2017-08-01 | Signal Pharmaceuticals, Llc | Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof |
| NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
| EA201790189A1 (ru) | 2014-07-14 | 2017-11-30 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Способы лечения злокачественного новообразования с использованием замещенных пирролопиримидиновых соединений, композиции на их основе |
| NZ629796A (en) | 2014-07-14 | 2015-12-24 | Signal Pharm Llc | Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
| CN105820086A (zh) * | 2015-01-05 | 2016-08-03 | 齐鲁工业大学 | 一种5-[3-（2,5-二乙氧基-4-甲磺酰基-苄基）-脲基]-2-乙氧基苯甲酸甲酯新化合物、制备方法及用途 |
| CN105820085A (zh) * | 2015-01-05 | 2016-08-03 | 齐鲁工业大学 | 一种乙磺酸{4-[3-（3-溴-苯基）-脲基甲基]-2,5-二乙氧基-苯基}-酰胺新化合物、制备方法及用途 |
| CN105820081A (zh) * | 2015-01-05 | 2016-08-03 | 齐鲁工业大学 | 一种5-[3-（2,5-二乙氧基-4-甲磺酰基-苄基）-脲基]-2-乙氧基-n-丙基-苯甲酰胺新化合物、制备方法及用途 |
| CN105820075A (zh) * | 2015-01-05 | 2016-08-03 | 齐鲁工业大学 | 一种n-{4-[3-（3,4-二甲氧基-苯基）-脲基甲基]-2,5-二乙氧基-苯基}-甲磺酰胺新化合物、制备方法及用途 |
| CN105820083A (zh) * | 2015-01-05 | 2016-08-03 | 齐鲁工业大学 | 一种5-[3-（2,5-二乙氧基-4-甲磺酰基-苄基）-脲基]-2-乙氧基-n-苯基-苯甲酰胺新化合物、制备方法及用途 |
| CN105820090A (zh) * | 2015-01-05 | 2016-08-03 | 齐鲁工业大学 | 一种5-[3-（2,5-二乙氧基-4-甲磺酰基-苄基）-脲基]-2-乙氧基-n-（3-甲氧基-苯基）-苯甲酰胺新化合物、制备方法及用途 |
| CN105820067A (zh) * | 2015-01-05 | 2016-08-03 | 齐鲁工业大学 | 一种n-{[2,5-二乙氧基-4-[（3-苯基-脲基）-甲基]-苯基}-甲磺酰胺新化合物、制备方法及用途 |
| CN105820084A (zh) * | 2015-01-05 | 2016-08-03 | 齐鲁工业大学 | 一种5-[3-（2,5-二乙氧基-4-甲磺酰基-苄基）-脲基]-2-丙氧基-苯甲酸甲基酯新化合物、制备方法及用途 |
| CN105820091A (zh) * | 2015-01-05 | 2016-08-03 | 齐鲁工业大学 | 一种基于3，4-二甲氧基苯基的取代苯甲酰胺新化合物、制备方法及用途 |
| CN105820068A (zh) * | 2015-01-05 | 2016-08-03 | 齐鲁工业大学 | 一种n-{4-[3-（3-溴-苯基）-脲基甲基]-2,5-二丙氧基-苯基}-甲磺酰胺新化合物、制备方法及用途 |
| CN105820078A (zh) * | 2015-01-05 | 2016-08-03 | 齐鲁工业大学 | 一种2-苄氧基-5-[3-（2,5-二乙氧基-4-甲磺酰基-苄基）-脲基]-苯甲酸甲酯新化合物、制备方法及用途 |
| CN105820092A (zh) * | 2015-01-05 | 2016-08-03 | 齐鲁工业大学 | 一种基于取代脲基的取代苯甲酸甲基酯新化合物、制备方法及用途 |
| CN105820094A (zh) * | 2015-01-05 | 2016-08-03 | 齐鲁工业大学 | 一种基于4-甲氧基-苄基的取代苯甲酰胺新化合物、制备方法及用途 |
| AU2016205361C1 (en) | 2015-01-06 | 2021-04-08 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
| CN105837476A (zh) * | 2015-01-12 | 2016-08-10 | 齐鲁工业大学 | 一种n-{4-[3-（3-溴-苯基）-脲基甲基]-2,5-二乙氧基-苯基}-甲磺酰胺新化合物、制备方法及用途 |
| CN106167456A (zh) * | 2015-05-20 | 2016-11-30 | 齐鲁工业大学 | 新型脲类蛋白酪氨酸磷酸酯酶1b抑制剂及其制备方法、药物组合物和用途 |
| PL3310760T3 (pl) | 2015-06-22 | 2023-03-06 | Arena Pharmaceuticals, Inc. | Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1 |
| KR20190116416A (ko) | 2017-02-16 | 2019-10-14 | 아레나 파마슈티칼스, 인크. | 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법 |
| ES2959860T3 (es) | 2017-06-22 | 2024-02-28 | Celgene Corp | Tratamiento del carcinoma hepatocelular caracterizado por la infección por el virus de la hepatitis B |
| WO2019190822A1 (en) | 2018-03-28 | 2019-10-03 | Vtv Therapeutics Llc | Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine |
| WO2019190823A1 (en) | 2018-03-28 | 2019-10-03 | Vtv Therapeutics Llc | Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine |
| AU2019280822A1 (en) | 2018-06-06 | 2021-01-07 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
| JP7464591B2 (ja) | 2018-10-10 | 2024-04-09 | ブイティーブイ・セラピューティクス・エルエルシー | ［３－（４－｛２－ブチル－１－［４－（４－クロロ－フェノキシ）－フェニル］－１ｈ－イミダゾール－４－イル｝－フェノキシ）－プロピル］－ジエチル－アミンの代謝産物 |
| CN118873532B (zh) * | 2024-10-09 | 2025-02-07 | 浙大城市学院 | 三取代吡唑化合物在制备抑制破骨细胞分化的药物中的应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001526643A (ja) * | 1997-04-18 | 2001-12-18 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | ５ｈｔ１ａ、５ｈｔ１ｂおよび５ｈｔ１ｄ受容体アンタゴニスト活性を合わせ持つ化合物を含む二環式アリールまたは二環式複素環 |
| AU7585498A (en) | 1997-05-23 | 1998-12-11 | Bayer Corporation | Inhibition of p38 kinase activity by aryl ureas |
| JP2001512727A (ja) * | 1997-08-09 | 2001-08-28 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | ５ｈｔ−１受容体のリガンドとしてのニ環式化合物 |
| US6080763A (en) * | 1997-11-03 | 2000-06-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds and their use as anti-inflammatory agents |
| ES2154253T3 (es) | 1997-12-22 | 2012-01-27 | Bayer Healthcare Llc | Inhibición de la actividad de p38 cinasa usando ureas heterocíclicas sustituidas. |
| WO1999032110A1 (en) | 1997-12-22 | 1999-07-01 | Bayer Corporation | INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS |
| WO1999032463A1 (en) * | 1997-12-22 | 1999-07-01 | Bayer Corporation | INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS |
| CA2332957A1 (en) | 1998-06-05 | 1999-12-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents |
| GB9823873D0 (en) | 1998-10-30 | 1998-12-30 | Pharmacia & Upjohn Spa | 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents |
| AU3126700A (en) * | 1998-12-18 | 2000-07-03 | Du Pont Pharmaceuticals Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| UA73492C2 (en) | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
| EP1163236B1 (en) | 1999-03-12 | 2005-11-09 | Boehringer Ingelheim Pharmaceuticals Inc. | Aromatic heterocyclic compounds as anti-inflammatory agents |
| HUP0202248A3 (en) * | 1999-03-12 | 2006-06-28 | Boehringer Ingelheim Pharma | Compounds useful as anti-inflammatory agents |
| NZ513639A (en) | 1999-04-15 | 2004-02-27 | Bristol Myers Squibb Co | Cyclic protein tyrosine kinase inhibitors |
| MXPA02004879A (es) | 1999-11-16 | 2002-08-30 | Boehringer Ingelheim Pharma | Derivados de urea como agentes antiinflamatorios. |
-
2002
- 2002-10-11 JP JP2003535792A patent/JP2005506350A/ja active Pending
- 2002-10-11 WO PCT/US2002/032809 patent/WO2003032989A1/en not_active Ceased
- 2002-10-11 CA CA002462441A patent/CA2462441A1/en not_active Abandoned
- 2002-10-11 US US10/269,173 patent/US6825184B2/en not_active Expired - Lifetime
- 2002-10-11 EP EP02801703A patent/EP1438048A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2903288C (en) | N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities | |
| JP5173192B2 (ja) | プロトンポンプ阻害薬 | |
| EP3416948B1 (en) | Indacene bearing sulfonylureas as anti-inflammatory agents | |
| US11059805B2 (en) | Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use thereof | |
| KR101470039B1 (ko) | 2-아릴-6-페닐이미다조〔1,2-α〕피리딘 유도체, 그의 제조법 및 그의 치료 용도 | |
| TWI776994B (zh) | 經碸吡啶烷基醯胺取代之雜芳基化合物 | |
| JP6854386B2 (ja) | リゾホスファチジン酸受容体１（ｌｐａｒ１）阻害剤化合物 | |
| CN107849049B (zh) | 脲衍生物或其药用盐 | |
| CA2483890A1 (en) | Substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses | |
| JP2004531571A5 (enExample) | ||
| CN111372931A (zh) | 作为蛋白激酶抑制剂的杂环化合物 | |
| JP2022551972A (ja) | Ｐｄ－ｌ１疾患の治療のためのヘテロアリール－ビフェニルアミン | |
| WO2007102512A1 (ja) | ４－オキソキノリン化合物の製造方法 | |
| EP3134402A1 (en) | 4-amino-imidazoquinoline compounds | |
| TWI788343B (zh) | 治療用化合物 | |
| JP6334066B2 (ja) | ヤヌスキナーゼ阻害剤としての置換されたＮ−（ピロリジン−３−イル）−７Ｈ−ピロロ［２，３−ｄ］ピリミジン−４−アミン | |
| JP2006514940A5 (enExample) | ||
| AU2019206560B2 (en) | Novel processes and intermediates for the preparation of soluble guanylate cyclase stimulators | |
| CA2507184A1 (en) | 1, 2, 3- triazole amide derivatives as cytokine inhibitors | |
| JP2010537994A5 (enExample) | ||
| CN105980362A (zh) | 含醚性氧原子的全氟烷基取代吡唑环化合物及其制造方法 | |
| AU679961B2 (en) | Novel quinolone carboxylic acid derivatives | |
| CN108137505B (zh) | 含氮杂环化合物 | |
| RU2530775C2 (ru) | ПРОИЗВОДНЫЕ 1Н-ПИРАЗОЛО[4,3-c]ИЗОХИНОЛИНОВ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ В ТЕРАПИИ | |
| CA2498754A1 (en) | Benzimidazolones and their use as cytokine inhibitors |